News

November 8, 2007

Amicus Therapeutics and Shire plc enter into $440 million ex-US Licensing Agreement to Develop and Commercialize Amigal™, Plicera™ and AT2220

November 7, 2007

Tengion - The Gray Sheet: Paving a Path to a Regenerative Medicine Industry.

November 1, 2007

Tranzyme Pharma Closes New $20 Million Financing

November 1, 2007

Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin® for RDS in Premature Infants

October 30, 2007

Health Day: Virus Shows Some Cancer-Killing Abilities

October 24, 2007

Tranzyme Pharma's Motilin Antagonist TZP-201 Shows Potential for Preventing and Treating Chemotherapy-Induced Diarrhea (CID)

October 15, 2007

Tengion Closes $33 Million in Series C Funding

October 9, 2007

Optherion, Inc. Completes $37 Million Start Up Financing

October 1, 2007

Surfaxin® Process Validation Batches Achieve Stability Milestone to Enable Filing of Response to FDA Approvable Letter

August 15, 2007

EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur®, a Novel Extended-Release Opioid Analgesic for Post Operative Pain

June 7, 2007

Pittsburgh Tribune Review: Medmark Co-Founder Shines

June 4, 2007

Celator Pharmaceuticals® Study Shows Anti-Tumor Activity in Cancer
Patients Treated with Therapy Based on Ratiometric Dosing

May 31, 2007

Amicus Therapeutics Announces Pricing of Initial Public Offering of 5,000,000 Shares of Common Stock

May 24, 2007

Biolex Therapeutics Raises $30 Million to Advance its Hepatitis C Drug Candidate and Other Pipeline Programs

May 21, 2007

NeuroStar TMS Therapy Improved Quality of Life in Patients with Major Depression in Clinical Trials

March 27, 2007

Regado Biosciences Completes $23 Million Series C Financing

March 21, 2007

Amicus Therapeutics Presents Positive Results from Phase 1 Clinical Studies of Plicera™ for Gaucher Disease

March 19, 2007

Amicus Therapeutics Presents Data from Preclinical and Phase 1 Studies of Amigal™ for Fabry Disease.

February 1, 2007

Pfizer to Acquire Biorexis to Access Novel Technology Platform and Early Stage Diabetes Pipeline.